Now Approved in Canada
Now Approved in Canada

NOW APPROVED IN CANADA

NOW APPROVED IN CANADA

Challenge Accepted
Challenge Accepted

To those who say “impossible, impractical, unrealistic,” we say:

Challenge Accepted

We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.

Our Pipeline
Our Pipeline

We are focused on diseases for which treatment options are limited or simply don’t exist.

Our Robust Pipeline

Includes investigational RNAi therapeutics for rare genetic, cardio-metabolic, hepatic infectious and CNS and ocular diseases.

WE ASPIRE TO CHANGE THE WAY MEDICINE TREATS DISEASE

Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of severe and debilitating diseases.

Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi discovery platform and deep pipeline of investigational medicines including one approved medicine (in the U.S., Europe and Canada), six programs in late-stage clinical development and multiple programs in early-stage clinical development.

>1k
Employees
16
Countries
10
Programs Currently in Clinical Development
1
Approved Product*
>35
Clinical Studies to Date
>5
Years Longest Duration of Exposure
>1k
Employees
16
Countries
10
Programs Currently in Clinical Development
1
Approved Product*
>35
Clinical Studies to Date
>5
Years Longest Duration of Exposure
Updated as of August 2019
*In the U.S., European Union, Canada and Japan

RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH

RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognized the importance of RNAi as a major scientific discovery.

Learn more ›

OUR FOCUS

Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall into 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases.

See our pipeline ›

JOIN OUR TEAM

Join Our Team

JOIN OUR TEAM

We are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles. We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted” to our mission.

View current job openings ›